Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMABELZ vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AMABELZ (amenamevir) is a helicase-primase inhibitor that inhibits the viral DNA replication by targeting the helicase-primase complex (UL5/UL52) of herpes simplex virus (HSV) and varicella-zoster virus (VZV).
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Herpes simplex virus (HSV) infections: cold sores (herpes labialis),Recurrent genital herpes,Herpes zoster (shingles)
Prevention of pregnancy
100 mg orally once daily.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal half-life of 4-6 hours; clinically relevant for dosing interval of 8-12 hours in normal renal function.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Primarily metabolized by CYP3A4. Minor contributions from CYP2C19 and CYP2D6.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Primarily renal (70-80% unchanged), with minor biliary/fecal elimination (10-15%).
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Approximately 30-40%, primarily to albumin.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.2-0.3 L/kg; indicates distribution mainly into extracellular fluid.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 70-80%; intravenous: 100%.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
e GFR 30-59 m L/min: 50 mg orally once daily. e GFR 15-29 m L/min: 25 mg orally once daily. e GFR <15 m L/min: not recommended.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Child-Pugh Class A: no adjustment. Child-Pugh Class B: 50 mg orally once daily. Child-Pugh Class C: not recommended.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
<12 years: not established. ≥12 years: 100 mg orally once daily.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
No specific adjustment; monitor renal function; consider lower doses based on creatinine clearance.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
No FDA black box warning.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Hepatotoxicity: Elevations in liver enzymes have been reported; monitor hepatic function.,Hypersensitivity reactions: Angioedema, urticaria, and anaphylaxis may occur.,Renal impairment: Dose adjustment required for moderate-to-severe renal impairment.,Carcinogenicity: No evidence in animal studies; however, long-term human data limited.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Hypersensitivity to amenamevir or any component of the formulation.,Severe hepatic impairment (Child-Pugh class C).
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Grapefruit and grapefruit juice should be avoided due to potential CYP3A4 interaction that may alter amivantamab exposure. No other specific food restrictions are known.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
FDA Pregnancy Category X. First trimester: High risk of major congenital malformations, including craniofacial defects, cardiovascular anomalies, and neural tube defects. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Contraindicated during breastfeeding. M/P ratio unknown; likely excreted in human milk based on molecular weight and lipid solubility. Potential for severe adverse effects in nursing infants.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Contraindicated in pregnancy; no dose adjustment recommended as therapy should be discontinued. If exposure occurs, immediate cessation of drug and close fetal monitoring advised.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
AMABELZ (amivantamab-vmjw) is a bispecific EGFR-MET antibody for NSCLC with EGFR exon 20 insertion mutations. Monitor for infusion-related reactions (premedicate), interstitial lung disease (hold if suspected), and venous thromboembolic events (prophylaxis recommended). Eye disorders including keratitis and uveitis occur; refer to ophthalmology if symptoms develop. Dermatologic toxicity (rash, dry skin) is common; manage with topical corticosteroids and emollients.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Do not drive or operate machinery if you experience dizziness, blurred vision, or photophobia.,Use sunscreen and protective clothing to prevent photosensitivity reactions.,Report new or worsening shortness of breath, cough, or fever immediately.,Use effective contraception during treatment and for 3 months after the last dose.,Avoid grapefruit and grapefruit juice as they may affect how the drug works.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMABELZ vs ALYACEN 7/7/7, answered by our medical review team.
AMABELZ is a Oral Contraceptive that works by AMABELZ (amenamevir) is a helicase-primase inhibitor that inhibits the viral DNA replication by targeting the helicase-primase complex (UL5/UL52) of herpes simplex virus (HSV) and varicella-zoster virus (VZV).. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMABELZ and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMABELZ is: 100 mg orally once daily.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMABELZ and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMABELZ is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of major congenital malformations, including craniofacial defects, cardiovascular anomalies, and neural tube defects. Second an. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.